JP2012530697A - ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物 - Google Patents
ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物 Download PDFInfo
- Publication number
- JP2012530697A JP2012530697A JP2012515987A JP2012515987A JP2012530697A JP 2012530697 A JP2012530697 A JP 2012530697A JP 2012515987 A JP2012515987 A JP 2012515987A JP 2012515987 A JP2012515987 A JP 2012515987A JP 2012530697 A JP2012530697 A JP 2012530697A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- present
- cancer
- effect
- hydroxychloroquine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (7)
- ヒドロキシクロロキン(hydroxychloroquine)またはその塩を含む抗癌治療のための局所投与用注射剤組成物。
- 癌細胞に直接注射または注入することを特徴とする請求項1に記載の抗癌剤の組成物。
- ヒドロキシクロロキンの塩が硫酸塩であることを特徴とする請求項1または2に記載の抗癌剤の組成物。
- ヒドロキシクロロキンが5〜25%(w/v)であることを特徴とする請求項1または2に記載の抗癌剤の組成物。
- ヒドロキシクロロキンが20%(w/v)であることを特徴とする請求項4に記載の抗癌剤の組成物。
- 局所麻酔剤及び抗酸化剤を追加で含むことを特徴とする請求項1または2に記載の抗癌剤の組成物。
- 局所麻酔剤としてリドカインを1〜2%(w/v)の濃度で含み、抗酸化剤としてリボフラビンを0.1〜0.5%(w/v)の濃度で含むことを特徴とする請求項6に記載の抗癌剤の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090056251A KR101208587B1 (ko) | 2009-06-24 | 2009-06-24 | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
KR10-2009-0056251 | 2009-06-24 | ||
PCT/KR2010/003938 WO2010151005A2 (ko) | 2009-06-24 | 2010-06-18 | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012530697A true JP2012530697A (ja) | 2012-12-06 |
JP5580409B2 JP5580409B2 (ja) | 2014-08-27 |
Family
ID=43387011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012515987A Expired - Fee Related JP5580409B2 (ja) | 2009-06-24 | 2010-06-18 | ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8506973B2 (ja) |
EP (1) | EP2465494A4 (ja) |
JP (1) | JP5580409B2 (ja) |
KR (1) | KR101208587B1 (ja) |
CN (1) | CN102481253B (ja) |
AU (1) | AU2010263479B2 (ja) |
BR (1) | BRPI1010073A2 (ja) |
RU (1) | RU2554497C2 (ja) |
WO (1) | WO2010151005A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017226643A (ja) * | 2016-06-20 | 2017-12-28 | ヨン ヨ,オ | キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物 |
JP2019135251A (ja) * | 2015-05-20 | 2019-08-15 | 大日本住友製薬株式会社 | Wt1抗原ペプチドおよび免疫調節剤の併用 |
JP2021130711A (ja) * | 2016-08-12 | 2021-09-09 | ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション | 軟組織硬化用組成物 |
US11759509B2 (en) | 2013-03-29 | 2023-09-19 | Sumitomo Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201809040T4 (tr) | 2011-03-21 | 2018-07-23 | Vivolux Ab | Solid tümörlerin tedavisi. |
CN102731393B (zh) * | 2012-06-27 | 2013-11-13 | 武汉武药科技有限公司 | 羟基氯喹衍生物及其合成方法 |
BR112015006370B1 (pt) | 2012-09-21 | 2022-04-12 | Vivolux Ab | Composto citotóxico, sal farmaceuticamente aceitável do mesmo, mistura, composição farmacêutica e uso do referido composto |
CN105982896A (zh) * | 2015-02-15 | 2016-10-05 | 广州中医药大学科技产业园有限公司 | 羟基氯喹在治疗或预防肿瘤中的用途 |
CN115317482A (zh) * | 2021-12-24 | 2022-11-11 | 南通大学附属医院 | 氯喹及其衍生物在制备改善鼻咽癌预后药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06199801A (ja) * | 1992-09-15 | 1994-07-19 | Sterling Winthrop Inc | (s)−(+)−ヒドロキシクロロキン |
JP2003524624A (ja) * | 1999-04-09 | 2003-08-19 | ジェシー エル エス オウ | 治療薬の組織への送達を高める方法及び組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100390332B1 (ko) | 2000-08-02 | 2003-07-07 | 유원민 | 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물 |
CA2595156A1 (en) * | 2005-01-19 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
EP2703011A3 (en) * | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2009
- 2009-06-24 KR KR1020090056251A patent/KR101208587B1/ko active IP Right Grant
-
2010
- 2010-06-18 AU AU2010263479A patent/AU2010263479B2/en not_active Ceased
- 2010-06-18 WO PCT/KR2010/003938 patent/WO2010151005A2/ko active Application Filing
- 2010-06-18 CN CN201080028073.1A patent/CN102481253B/zh not_active Expired - Fee Related
- 2010-06-18 JP JP2012515987A patent/JP5580409B2/ja not_active Expired - Fee Related
- 2010-06-18 BR BRPI1010073A patent/BRPI1010073A2/pt not_active IP Right Cessation
- 2010-06-18 EP EP10792287A patent/EP2465494A4/en not_active Withdrawn
- 2010-06-18 RU RU2012100622/15A patent/RU2554497C2/ru not_active IP Right Cessation
- 2010-06-18 US US13/380,042 patent/US8506973B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06199801A (ja) * | 1992-09-15 | 1994-07-19 | Sterling Winthrop Inc | (s)−(+)−ヒドロキシクロロキン |
JP2003524624A (ja) * | 1999-04-09 | 2003-08-19 | ジェシー エル エス オウ | 治療薬の組織への送達を高める方法及び組成物 |
Non-Patent Citations (3)
Title |
---|
JPN6013035185; BRITISH JOURNAL OF HAEMATOLOGY,2001.Vol.112,p.344-352 * |
JPN6013035187; ONCOGENE,2003,Vol.22,p.3927-3936 * |
JPN6013035188; 注射剤-その基礎と調剤と適用-,(株)南山堂,1995,p.21-23 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11759509B2 (en) | 2013-03-29 | 2023-09-19 | Sumitomo Pharma Co., Ltd. | WT1 antigen peptide conjugate vaccine |
JP2019135251A (ja) * | 2015-05-20 | 2019-08-15 | 大日本住友製薬株式会社 | Wt1抗原ペプチドおよび免疫調節剤の併用 |
JP2017226643A (ja) * | 2016-06-20 | 2017-12-28 | ヨン ヨ,オ | キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物 |
JP7105465B2 (ja) | 2016-06-20 | 2022-07-25 | ヨン ヨ,オ | キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法 |
JP2021130711A (ja) * | 2016-08-12 | 2021-09-09 | ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション | 軟組織硬化用組成物 |
US11773109B2 (en) | 2016-08-12 | 2023-10-03 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Composition for hardening soft tissue |
Also Published As
Publication number | Publication date |
---|---|
CN102481253B (zh) | 2014-06-25 |
WO2010151005A3 (ko) | 2011-05-19 |
US8506973B2 (en) | 2013-08-13 |
WO2010151005A2 (ko) | 2010-12-29 |
EP2465494A4 (en) | 2013-02-27 |
US20120095045A1 (en) | 2012-04-19 |
EP2465494A2 (en) | 2012-06-20 |
JP5580409B2 (ja) | 2014-08-27 |
BRPI1010073A2 (pt) | 2016-03-15 |
KR101208587B1 (ko) | 2012-12-06 |
RU2012100622A (ru) | 2013-07-27 |
RU2554497C2 (ru) | 2015-06-27 |
CN102481253A (zh) | 2012-05-30 |
AU2010263479A1 (en) | 2012-02-09 |
KR20100137962A (ko) | 2010-12-31 |
AU2010263479B2 (en) | 2014-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5580409B2 (ja) | ヒドロキシクロロキンを含む抗癌治療のための局所投与用注射剤の組成物 | |
KR101723265B1 (ko) | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
MXPA03010528A (es) | Metodos para inhibir angiogenesis. | |
WO2013075607A1 (zh) | 绿原酸的抗癌新用途 | |
CN109908143A (zh) | 西奥罗尼在制备治疗急性髓系白血病药物的新用途 | |
US20210330626A1 (en) | Pharmaceutical composition for treating kidney cancer and application thereof | |
CN111973631A (zh) | 牙髓间充质干细胞在制备阿尔茨海默病治疗药物中的用途 | |
CN108295085B (zh) | 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用 | |
CN111803484B (zh) | 奥替溴铵在制备抗肿瘤药物中的应用 | |
CN110038030A (zh) | 抗鼻咽癌活性组合物、化疗药物及其应用 | |
US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
CN111920814B (zh) | 依匹哌唑在制备抗肿瘤药物中的应用 | |
CN110664807B (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
JP7105465B2 (ja) | キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法 | |
CN105560224A (zh) | 盐霉素在制备抑制血管新生药物中的应用 | |
CN111821303A (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
CN111773388A (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
JP2017226643A5 (ja) | ||
KR101606645B1 (ko) | 다우리놀 화합물을 유효성분으로 포함하는 면역질환의 예방 및 치료용 조성물 | |
CN110772507B (zh) | 盐酸胍作为治疗癌症/肿瘤的药物的用途 | |
KR20120026208A (ko) | Sta-21을 유효성분으로 함유하는 암 또는 면역질환의 예방 및 치료용 조성물 | |
CN101401820B (zh) | 一种治疗系统性红斑狼疮注射液 | |
CN111035758A (zh) | 药物组合物及其应用、无菌容器和试剂盒 | |
CN111904957A (zh) | 奥昔卡因在制备抗肿瘤药物中的应用 | |
CN109453195A (zh) | 一种用于抑制肿瘤细胞的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131016 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131023 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140527 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140610 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5580409 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |